Full text
Earnings transcript
Read the complete earnings call transcript.
INDV
Indivior Pharmaceuticals Inc
$30.47
-0.18
(-0.59%)
| Exchange: | NASDAQ |
| Market Cap: | 3.802B |
| Shares Outstanding: | 143.975M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – Specialty & Generic | |||||
| CEO: | Joseph J. Ciaffoni | |||||
| Full Time Employees: | 1030 | |||||
| Address: |
| |||||
| Website: | https://www.indivior.com |
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,093,000 | 1,188,000 | 1,239,000 |
| Gross Profit | 919,000 | 957,000 | 994,000 |
| EBITDA | -99,000 | 84,000 | 304,000 |
| Operating Income | -156,000 | 32,000 | 262,000 |
| Net Income | -129,000 | 2,000 | 210,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,954,000 | 1,319,000 | 1,201,000 |
| Total Liabilities | 1,951,240.978 | 1,668,000 | 1,300,000 |
| Total Stockholders Equity | 67,903.984 | -348,000 | -99,000 |
| Total Debt | 282,000 | 375,000 | 61,000 |
| Cash and Cash Equivalents | 316,000 | 319,000 | 195,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -315,000 | 36,000 | -27,000 |
| Capital Expenditure | -53,000 | -29,000 | -66,000 |
| Free Cash Flow | -368,000 | 7,000 | -93,000 |
| Net Income | 2,048.184 | 2,000 | 210,000 |
| Net Change in Cash | -458,000 | 3,000 | -124,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,344,127.936 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,423,673.395 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,379,100 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 127,778.287 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 135,340.203 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 131,102.874 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 513,070.084 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 552,852.484 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 530,560.004 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 703,759.362 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 745,407.824 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 722,070.058 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.150 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.320 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 4.010 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: INDV has demonstrated strong revenue figures as reported in the latest income statements, with consistent growth over recent periods. This indicates a solid operational foundation and market demand for its products or services within the industry.
- Positive Free Cash Flow: The cash flow statements highlight a healthy free cash flow yield (freeCashFlowYieldTTM), suggesting efficient capital management and the ability to fund operations, invest in growth, and potentially return value to shareholders.
- Favorable Valuation Metrics: The current price-to-earnings ratio (priceToEarningsRatioTTM) and forward P/E estimates (forward_pe_avg) suggest that INDV is reasonably valued compared to industry averages (industry_avg_priceToEarningsRatioTTM), potentially indicating an attractive investment opportunity.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates INDV intrinsic value between $0.77 – $19.79 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about INDV valuation
Is Indivior Pharmaceuticals Inc (INDV) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Indivior Pharmaceuticals Inc (INDV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is INDV a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether INDV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is INDV’s P/E ratio?
You can see INDV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for INDV?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is INDV a good long-term investment?
Whether INDV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
INDV
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.59
Trading Metrics:
| Open: | 29.99 | Previous Close: | 30.65 | |
| Day Low: | 29.65 | Day High: | 30.57 | |
| Year Low: | 8.64 | Year High: | 38 | |
| Price Avg 50: | 32.54 | Price Avg 200: | 27.47 | |
| Volume: | 1.809M | Average Volume: | 2.397M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeINDV full analysis
Welcome to MARKETSNAP’s SWOT analysis for Indivior PLC, a company that’s carving out its space in the healthcare sector with a focus on specialty pharmaceuticals. If you’re a long-term investor looking to diversify into niche medical solutions, stick around as we break down what makes Indivior tick, where it’s stumbling, and what the future might hold. Let’s dive into the nitty-gritty with a conversational deep dive into their strengths, weaknesses, opportunities, and threats, while keeping an eye on both short-term…
